Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,591 people get NBS articles and Market Currents by email alert.
Get email alerts on NBS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (Thu, 7:30AM)
-
-
GlobeNewswire (May 14, 2013)
-
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 9, 2013)
-
-
GlobeNewswire (May 3, 2013)
-
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 29, 2013)
-
GlobeNewswire (Apr 29, 2013)
-
GlobeNewswire (Apr 29, 2013)
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
There are no Transcripts on NBS.
-
GlobeNewswire (Thu, 7:30AM)
-
GlobeNewswire (May 14, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 3, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 29, 2013)
-
GlobeNewswire (Apr 29, 2013)
-
GlobeNewswire (Apr 29, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 28, 2013)
-
GlobeNewswire (Mar 19, 2013)
-
GlobeNewswire (Mar 13, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 11, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Feb 4, 2013)
NBS vs. ETF Alternatives
Company Description
NeoStem, Inc. engages in the development of proprietary cell therapy products. It is involved in the manufacture of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. The... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 3:38 PM NeoStem (NBS +1.5%) holds in the green today after the company announced the geographic patent expansion of its lead product candidate, AMR-001, with the notice of a grant in Malaysia and notice of recommendation for allowance in the Philippines. These patents are in the family of US patent titled "Compositions and Methods of Vascular Injury Repair" and protected a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction. Comment! [Healthcare, Global & FX, On the Move]
- Thursday, May 16, 10:46 AM Shares of stem cell research firms are rallying today on the back of an announcement today by the Oregon Health and Science University that they've successfully reproduced human stem cells by cloning. Cloning stem cells in this fashion could lead to cell therapies using a patient’s own cells and thereby avoid the problems of immune suppression: StemCells (STEM +2.2%), NeuralStem (CUR +2.1%), NeoStem (NBS +2.2%). Comment! [Healthcare, On the Move]
- Thursday, May 16, 8:07 AM NeoStem (NBS) has its patent application for AMR-001 granted in Malaysia and appears close to a similar result in the Philippines. The company also says it has been granted a second patent in South Africa. AMR-001 (which will have 9 total patents after today's announcement) is the company's flagship product and NBS intends to complete enrollment in a Phase II trial this year. SA contributor Equity Options Guru is bullish based on what he believes are improving balance sheet dynamics. (PR) Comment! [Healthcare]
- Thursday, May 9, 4:54 PM NeoStem (NBS): Q1 EPS of -$0.05 in-line. (PR) 5 Comments [Earnings, Breaking News, Healthcare]
- Monday, April 29, 6:40 PM NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working capital, including research and development of cell therapeutic product candidates, including AMR-001, plus expansion of its business units, strategic transactions and other general corporate purposes. Terms and size of the offering have not yet been disclosed. Aegis Capital is acting as sole book-running manager. Shares -8% AH. 3 Comments [Healthcare, On the Move]
- Wednesday, March 13, 9:32 AM NeoStem (NBS) unit Amorcyte receives a Notice of Allowance of claims from the U.S. Patent office for an application that covers a new way to treat damage to the heart muscle that's caused by a reduced blood supply and that utilizes a multi-dosing regimen. A major condition covered is the use of Amorcyte's AMR-001 for treating ischemia-induced congestive heart failure, which affects 5.8M people in the U.S. and 20M globally. (PR) Comment! [Healthcare]
- Thursday, March 7, 8:11 AM NeoStem (NBS +3.8%) has received approval to continue the Phase II trial of its AMR-001 heart treatment following a second interim data and safety review by the Data Safety Monitoring Board. NeoStem is testing AMR-001 for the prevention of further major problems following heart attacks and hopes to complete enrollment in the study this year. (PR) Comment! [Healthcare, On the Move]
- Wednesday, November 14, 2012, 9:01 AM NeoStem (NBS): Q3 EPS of -$0.06 misses by $0.01. Revenue of $4.4M beats by $0.9M. (PR) Comment! [Earnings, Healthcare]
- Friday, August 24, 2012, 4:34 PM NeoStem (NBS) files a secondary offering to sell 22.97M shares of common stock for holders. Shares +3% AH. 4 Comments [Healthcare, On the Move]
- Monday, June 18, 2012, 12:06 PM Neostem (NBS +1.6%) agrees to sell 51% of its interest in Suzhou Erye Pharmaceutical, a China-based generic pharmaceutical company, for $12.3M in cash. Included in the agreement is the the return to the company of 1.04M shares of common stock and the cancellation of 1.17M options and 640K common stock warrants, which collectively represent 1.3% of NBS' outstanding shares. Comment! [Global & FX, Healthcare, On the Move]
-
pagreen1966
Intend to purchase a shedful of $NBS shares today. The secondary offering has pushed the stock price down 22% in pre-market trading! - View all 0 replies
-
- View all 0 replies
-
jsiebel720
$NBS: Anyone hear anything why the stock is trading the way it is. Called IR contact; Worthless & waste oftime. Any feedback is appreciated - View all 5 replies
-
jjwatts: bunch of pumpers all over the place is what i see, the company has potential so the pumpers are trying to take advantage of ppl -
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
- View all 0 replies
-
- View all 3 replies
-
Fincher: a bit stronger word on mi side, fair play to you. just wanted to express a tad of frustration for a lack of upward momentum.
-
gbstern13: Get used to it. Development stage biotech; long bouts of sideways drifting occasionally interrupted with sharp movement. Par for the course.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
VFC's Stock House
$AMRN, $NBS, $AEZS, $ONTY, $SSH - Five share price dips that might just be temporary ... http://bit.ly/S1AJE7 - View all 0 replies
LATEST REPLIES
-
jsiebel720
$NBS: Anyone hear anything why the stock is trading the way it is. Called IR contact; Worthless & waste oftime. Any feedback is appreciated - View all 5 replies
-
jjwatts: bunch of pumpers all over the place is what i see, the company has potential so the pumpers are trying to take advantage of ppl
-
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
Michael Bryant
Complete Genomics (GNOM) and its DNA sequencing technology looks good. But Neostem (NBS) and stem cells...no. http://yhoo.it/KSyRFj - View all 6 replies
-
-
The Berenstain Bulls: @Maria: Yeah, I like GNOM as well, currently long a few shares.
-
- View all 3 replies
-
Fincher: a bit stronger word on mi side, fair play to you. just wanted to express a tad of frustration for a lack of upward momentum.
-
gbstern13: Get used to it. Development stage biotech; long bouts of sideways drifting occasionally interrupted with sharp movement. Par for the course.
-
- View all 7 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
The Berenstain Bulls
PSTI, NBS, GNOM, and Nuvilex (NVLX) all looking swaggish as of late. http://bit.ly/P32kkI - View all 1 replies
-
-
Husky Financial
NBS up 90% since i posted about it 3 months ago.. only person i know to have taken the advice was BernsteinBears congrat$ man - View all 2 replies
-
-
-
- View all 1 replies
-
-
benjikrigs
Does anyone else agree that its probably the same people who buy AAPL at 650 that naysay NBS at under 60 cents. I am long NBS. - View all 2 replies
-
-
-
Todd Theman
Lots of cash, no debt, several possible catalysts for NBS including possible sale of their Chinese subsidiary. Buying small position here. - View all 1 replies
-
